# XWPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xwpharma

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.xwpharma.com
- Total disclosed funding: $58M
- Latest round: Series C (Sep 17, 2020)
- Investors on record: 10

## About

Established in 2014 and based in Wuhan, China, XWPharma Ltd. operates as a new drug development company dedicated to design and develop new drugs for central nervous system disorders. The founder and CSO of the company, Jianing Xiang graduated from California Institute of Technology and has worked in SmithKline Beecham. The CMO of the company, Daniel Canafax graduated from Washington State University and was a professor of pharmacy, surgery, and otolaryngology at the University of Minnesota. In September 2020, the company raised USD 40 million in series C funding led by new investor Panacea Venture.

The company mainly develops biopharmaceuticals for neurological diseases. It has three pipelines, which are Valiloxybate, XW10508, and other programs. The Valiloxybate can be used for Narcolepsy and Non-motor Symptoms of Parkinson’s disease. The XW10508 can be applied to major depressive disorder (MDD) and chronic pain. 

The company generates revenue by providing biopharmaceuticals for neurological diseases.

## Funding rounds

- Series C, Sep 17, 2020, $40M — CDIB Capital Group, Johnson & Johnson Innovation, WI Harper Group, Trinity Funds, WOORI Venture Partners, Wuxi Huading Venture Capital, Orient Hontai Capital-, Panacea Venture
- Series B, Sep 20, 2017, $18M — Kleiner Perkins, Johnson & Johnson Innovation, WI Harper Group, WOORI Venture Partners, ECM Partners, Wuxi Huading Venture Capital
- Series A, Sep 1, 2014 — Kleiner Perkins, Johnson & Johnson Innovation

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B, Series C
- WI Harper Group (https://capitalatlas.ai/funds/wi-harper-group) — Series B, Series C
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series B, Series C
- ECM Partners (https://capitalatlas.ai/funds/ecm-partners) — Series B
- Wuxi Huading Venture Capital (https://capitalatlas.ai/funds/wuxi-huading-venture-capital) — Series B, Series C
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series C
- Trinity Funds — Series C
- Orient Hontai Capital- — Series C
- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Series C